Amuc_1100 and Checkpoint Modulator Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immune checkpoint modulator therapies for cancer exhibit variable efficacy across different cancer types, with limited long-term responses and resistance issues, and there is a need for effective combination therapies to enhance cancer treatment outcomes.
Innovation Solution
Administering a gut immunity modulator, such as Amuc_1100 or a genetically engineered host cell expressing Amuc_1100, in combination with an immune checkpoint modulator to enhance gut immunity and improve therapeutic responses in cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint modulator drugs are used to treat cancer, then cancer treatment efficacy is improved, but response rates vary among cancer types and disease progression develops
Solution Approach 1:
The patent combines immune checkpoint modulators with gut microbiota-based therapies (probiotics, prebiotics, fecal microbiota transplantation) to create a multi-modal treatment approach. This merging of different therapeutic mechanisms addresses the variability in response rates across cancer types by engaging both the immune checkpoint pathway and the gut-immune axis simultaneously.
Solution Approach 2:
The patent introduces gut microbiota components (specific bacteria strains, metabolites like butyrate, propionate, acetate) as intermediary agents that modulate the immune system's response to checkpoint inhibitors. These microbiota-derived mediators enhance T-cell activation, reduce immunosuppression in the tumor microenvironment, and improve overall treatment efficacy across different cancer types.
2Reliability
If immune checkpoint modulator drugs are administered, then initial response is achieved, but long-term benefit is limited to small population
Solution Approach 1:
The patent employs preliminary modulation of the gut microbiota before and during immune checkpoint inhibitor treatment. By pre-conditioning the gut microbiome with probiotics, prebiotics, or microbiota-based therapies, the patent aims to prime the immune system for sustained response and prevent resistance development, thereby extending long-term benefit.
Solution Approach 2:
The patent establishes continuous gut microbiota modulation throughout the treatment course, maintaining beneficial microbial populations and their metabolite production. This continuous action ensures sustained immune system activation and prevents disease progression, converting initial responders into long-term beneficiaries.
3Reliability
If combination therapy with immune checkpoint modulators is developed, then therapeutic efficacy can be enhanced, but none has been proven highly effective yet
Solution Approach 1:
The patent identifies universal gut microbiota components and mechanisms (specific bacterial strains, conserved metabolite pathways) that can enhance immune checkpoint inhibitor efficacy across multiple cancer types. This universal approach simplifies combination therapy development by focusing on common microbiota-based interventions rather than cancer-type-specific complex regimens.
Data Source
AI summary
The present disclosure provides a composition comprising Amuc_1100 (or a genetically engineered host cell expressing the Amuc_1100) and an immune checkpoint modulator, and uses thereof.